TABLE 4.
Predictive impact of biomarker gene signatures in NSCLC patients treated with complete resection with or without ACT
| First author [ref.] | Subjects n | Treatment | Stage | Method | Biomarker | Biomarker expression | Disease-free survival | Overall survival | ||||
| Survival | p-value1 | Survival | p-value | |||||||||
| Univariate | Multivariate | Univariate | Multivariate | |||||||||
| Van Laar [53] | 109 | ACT (CDDP + NVB) or OP# | I–II | Genomic profiling | 37-gene signature | Predicted ACT-responder (ACT versus OP) | NA | NA | NA | HR: 0.23 (0.08–0.61) | NA | 0.0032 |
| Predicted nonresponder (ACT versus OP) | NA | NA | NA | HR: 0.55 (0.15–2.04) | NA | 0.38 | ||||||
| Zhu [31] | 133 | ACT (CDDP + NVB) or OP# | IB–II | RT-PCR | 15-gene signature | High risk signature (ACT versus OP) | NA | NA | NA | HR: 0.4 (0.18–0.90) | 0.017 | NA |
| Low risk signature (ACT versus OP) | NA | NA | NA | HR: 1.28 (0.65–2.52) | 0.476 | NA | ||||||
| Chen [32] | 133 | ACT (CDDP + NVB) or OP# | I–III | DNA microarray | 92-gene signature | High risk signature (ACT versus OP) | NA | NA | NA | 72.2% versus 39.2% | 0.03 | NA |
| Low risk signature (ACT versus OP) | NA | NA | NA | 71.4% versus 70.4% | 0.24 | NA | ||||||
| Wistuba [34] | 207 | ACT (NA) or OP¶ | I–IIB | qPCR | 31-gene signature | High CCP score | NA | NA | NA | Greater absolute ACT benefit | 0.0060 | 0.024 |
Survival data are presented as hazard ratio (HR) (95% CI) or % 5-year survival. NSCLC: nonsmall cell lung cancer; ACT: adjuvant chemotherapy; CDDP: cisplatin; NVB: vinorelbine; OP: complete surgery only; NA: not available; RT-PCR: reverse transcriptase PCR; qPCR: quantitative PCR; CCP: cell cycle progression gene. #: randomised trial, ACT group and OP group (control group); ¶: not randomised patients, ACT group and OP group (control group).